###### Strengths and limitations of this study

-   This is the first nationwide propensity score-matched cohort study to evaluate the risk of pleural empyema in patients with schizophrenia.

-   The National Health Insurance programme of Taiwan have covered \>99% of 23.74 million people.

-   Universal coverage reduces barriers to healthcare access for all citizens.

-   The International Classification of Diseases, Ninth Revision, Clinical Modification algorithm was used to define diseases and an ad hoc committee was in charge to monitor the claims data to prevent errors and violation of confidentiality.

-   The database does not provide detailed information on lifestyles and other psychosocial and environmental factors.

-   Relevant clinical variables such as serum laboratory data and image reports were unavailable in the database.

Introduction {#s1}
============

Patients with pleural empyema require prompt and timely treatments, such as antibiotic therapy, pleural space drainage, intrapleural fibrinolysis and/or surgery.[@R1] Approximately 60 000 cases of pleural empyema are diagnosed annually in the USA.[@R3] The condition is more prevalent in Taiwan, with the incidence rates ranging from 0.96 to 8.19 per 10 000 person-years.[@R4] Alcoholism, drug abuse, diabetes mellitus, immunocompromised status, neoplasm and pre-existent pulmonary disease or pleural effusion are risk factors for the development of pleural empyema.[@R7] Patients with pleural empyema and comorbid with chronic illness are at a poorer prognosis and a greater risk of mortality.[@R9]

Schizophrenia is a severe mental disorder, characterised by profound disruptions in thinking, affecting language, perception and the sense of self.[@R11] The hallmark symptom of schizophrenia is psychosis, such as experiencing auditory hallucinations and delusions.[@R12] Approximately 0.3%--0.7% of individuals are affected by schizophrenia during their lifetime, and thus, schizophrenia affects \>21 million people worldwide.[@R13] People with schizophrenia are at a markedly increased risk of premature death. Despite elevated rates of suicide and other unnatural causes of death, most of the excess mortality has been attributed to cardiovascular disease, respiratory disease and other natural causes.[@R14]

Patients with schizophrenia have been associated with a higher risk of thoracic infections.[@R15] The risk of having pneumonia is threefold greater in patients with schizophrenia than in general population.[@R16] Unhealthy lifestyle, lack of self-care, poorer physical circumstances and health-risk activities may contribute to this condition.[@R13] Furthermore, patients with schizophrenia suffering from these infections may have poorer clinical outcomes, such as acute respiratory failure, the use of mechanical ventilation, intensive care unit admission and hospital death.[@R16] Thoracic infection and pneumonia greatly increase morbidity and mortality in patients with schizophrenia and seriously threaten the health of these patients. However, the association between schizophrenia and the occurrence of pleural empyema, an advanced and specific thoracic infection, remains unclear.

The National Health Insurance Research Database (NHIRD) in Taiwan is a nationwide database containing the medical claims data of 23 million residents. These reliable data have been used in studies on various disorders, including schizophrenia and pleural empyema.[@R6] The present study aims to investigate whether patients with schizophrenia are at an increased risk of subsequent occurrence of pleural empyema. In addition to estimate the incidence of pleural empyema in persons with and without schizophrenia, we also compared the 30-day mortality from pleural empyema between the two cohorts.

Materials and methods {#s2}
=====================

Data source {#s2a}
-----------

The universal health insurance of Taiwan covers \>99% of the Taiwanese population. Information on demographic status of insured people and their medical services received were available in the NHIRD obtained from the National Health Research Institutes. Patient identifiers were re-encoded before the release of NHIRD to protect the patient privacy.

Study population {#s2b}
----------------

Pleural empyema is one of the diseases among 30 categories of catastrophic illnesses classified in the insurance system, requiring long-term and/or extensive care, similar to cancers, end-stage major organ diseases, systemic autoimmune diseases and major mental disorders. After a careful peer-review process, patients registered with a catastrophic illness certificate are eligible for reduced financial burden for healthcare.

For the present study, we used a subset data of NHIRD, the Longitudinal Health Insurance Database 2000 (LHID2000), which contains health data of 1 million people randomly selected from 23 million people. From the database, we identified patients with schizophrenia aged 20 years and older newly diagnosed in 2000--2011 (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 295), without the history of pleural empyema (ICD-9-CM code 510) as the schizophrenia cohort. The comparison cohort were randomly selected from individuals without schizophrenia and pleural empyema from the LHID2000 file, using a 1:1 ratio, frequency matched by propensity scores. The propensity score was estimated to reduce bias from baseline variables, including age, sex, occupation, monthly income, urbanisation level and comorbidities of diabetes (ICD-9-CM code 250), asthma (ICD-9-CM code 493), chronic obstructive pulmonary disease (COPD) (ICD-9-CM code 496), chronic liver disease and cirrhosis (CLD) (ICD-9-CM code 571), cancer (ICD-9-CM codes 140--208), systemic lupus erythematosus (SLE)/rheumatoid arthritis (RA)/immune diseases (ICD-9-CM codes 710.0, 714.0, 279), organ transplant (ICD-9-CM code V42), malnutrition (ICD-9-CM codes 260--269), obesity (ICD-9-CM code 278.0), alcohol abuse (ICD-9-CM codes 291, 303, 305.0), drug abuse (ICD-9-CM codes 292, 304, 305.2, 305.9) and tobacco use disorder (ICD-9-CM code 305.1).

Patient and public involvement {#s2c}
------------------------------

This retrospective cohort study used the secondary data of insurance claims with anonymised identifications. Therefore, we considered that patients and public were not involved.

Outcome {#s2d}
-------

The main outcome of this study was pleural empyema. Person-years indicated the sum of the follow-up time for all participants, and the follow-up time was defined as the time from the index date to the diagnosis of pleural empyema, death, withdrawal from the insurance or the end of 2011.

Statistical analysis {#s2e}
--------------------

The two study groups were matched by the propensity scores, and the standardised difference was used to quantify differences in means or prevalence rates between schizophrenia and comparison cohorts for continuous or categorical variables, respectively. A standardised difference of 0.1 or less indicated a negligible difference between two cohorts.[@R23] The incidence rate of pleural empyema was estimated per 10 000 person-years. We used Poisson regression analysis to calculate the patients with schizophrenia to controls incidence rate ratio (IRR). The Kaplan-Meier method was then used to calculate and plot the cumulative incidence of pleural empyema for each cohort and the difference between the two curves was examined using log-rank test. Multivariable Cox proportional hazards regression analysis was used to estimate the adjusted HR (aHR) and 95% CI for the two groups. The multivariable model included variables of age, sex, occupation, monthly income, urbanisation level and comorbidities of diabetes, asthma, COPD, CLD, malnutrition and alcohol abuse. Data analysis for this study was performed using SAS statistical software (V.9.4 for Windows; SAS Institute Cary, North Carolina, USA). Statistical significance was determined at p\<0.05.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} shows that schizophrenia and comparison cohorts were similar in distributions of baseline demographics and comorbidities with mean ages of 38.9 and 38.7 years, respectively.

###### 

Baseline characteristics compared between cohorts with and without schizophrenia

                             Schizophrenia   Standardised difference                   
  -------------------------- --------------- ------------------------- -------- ------ -------
  Age (years)                                                                          
   20--49                    43 651          78.1                      44 679   79.9   0.045
   50--64                    7083            12.7                      8654     15.5   0.081
   ≥65                       5154            9.22                      2555     4.57   0.18
   Mean (SD)                 38.7            16.2                      38.9     13.4   0.015
  Sex                                                                                  
   Women                     27 036          48.4                      26 796   48.0   0.009
   Men                       28 852          51.6                      29 092   52.1   0.009
  Occupation\*                                                                         
   Office worker             24 539          43.9                      24 844   44.5   0.011
   Labourer                  17 604          31.5                      17 499   31.3   0.004
   Other                     13 745          24.6                      13 545   24.2   0.008
  Monthly income†                                                                      
   \<15 000                  25 221          45.1                      24 985   44.7   0.008
   15 000--19 999            23 266          41.6                      23 696   42.4   0.016
   ≥20 000                   7401            13.2                      7207     12.9   0.01
  Urbanisation level‡                                                                  
   City                      29 894          53.5                      30 151   54.0   0.009
   Rural area                25 994          46.5                      25 737   46.1   0.009
  Comorbidity                                                                          
   Diabetes                  2442            4.37                      2485     4.45   0.004
   Asthma                    2204            3.94                      2245     4.02   0.004
   COPD                      3168            5.67                      3262     5.84   0.007
   CLD                       7134            12.8                      7249     13.0   0.006
   Cancer                    430             0.77                      417      0.75   0.003
   SLE/RA/immune disorders   32              0.06                      31       0.06   0.001
   Organ transplant          7               0.01                      7        0.01   0.000
   Malnutrition              362             0.65                      331      0.59   0.007
   Obesity                   719             1.29                      724      1.30   0.001
   Alcohol abuse             2922            5.23                      2884     5.16   0.003
   Drug abuse                1818            3.25                      1986     3.55   0.017
   Tobacco use disorder      843             1.51                      789      1.41   0.008

\*Other occupations include primarily retired, unemployed and low-income populations.

†1 new Taiwan dollar is equal to 0.03 US dollar.

‡The urbanisation level is categorised by the population density of the residential area into two levels: city and rural area.

CLD, chronic liver disease and cirrhosis; COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

After a mean follow-up time of 6.7 years in both cohorts, [figure 1](#F1){ref-type="fig"} shows that the cumulative incidence of pleural empyema was 0.34% higher in the schizophrenia cohort than in the comparison cohort. The incidence was 2.4-fold greater in patients with schizophrenia than in comparisons (4.39 vs 1.80 per 10 000 person-years), with an IRR of 2.44 (95% CI 1.83 to 3.24) or an aHR of 2.87 (95% CI 2.14 to 3.84) ([table 2](#T2){ref-type="table"}). The pooled data showed that the overall incidence increased with age, and higher in men than in women. Study population of low income and living in rural area were at higher risk of empyema. Individuals with comorbidities are also at increased risk of pleural empyema, including those with diabetes (aHR 2.62, 95% CI 1.77 to 3.87), asthma (aHR 1.98, 95% CI 1.27 to 3.07), COPD (aHR 2.01, 95% CI 1.38 to 2.95), malnutrition (aHR 3.60, 95% CI 1.76 to 7.36) and alcohol abuse (aHR 1.74, 95% CI 1.10 to 2.74).

![Cumulative incidence of pleural empyema in the schizophrenia cohort (dashed line) and the comparison cohort (solid line).](bmjopen-2017-021187f01){#F1}

###### 

Incidence of pleural empyema, IRR and aHR measured for pooled study population by study cohort, sociodemographic status and comorbidities

  ---------------------------------------------------------------------------------------------------------------
                             Event   PY        Rate†   IRR\                           aHR‡\
                                                       (95% CI)                       (95% CI)
  -------------------------- ------- --------- ------- ------------------------------ ---------------------------
  Schizophrenia                                                                       

   No                        67      371 984   1.80    1.00                           1.00

   Yes                       164     373 435   4.39    2.44 (1.83 to 3.24)\*\*\*      2.87 (2.14 to 3.84)\*\*\*

  Age (years)                                                                         

   20--49                    126     604 297   2.09    1.00                           1.00

   50--64                    65      97 993    6.63    3.19 (2.36 to 4.30)\*\*\*      2.86 (2.09 to 3.93)\*\*\*

   ≥65                       40      43 129    9.27    4.46 (3.13 to to 6.37)\*\*\*   3.45 (2.29 to 5.19)\*\*\*

  Sex                                                                                 

   Women                     52      360 369   1.44    1.00                           1.00

   Men                       179     385 050   4.65    3.22 (2.37 to 4.39)\*\*\*      3.52 (2.57 to 4.82)\*\*\*

  Occupation§                                                                         

   Office worker             79      328 927   2.40    1.00                           1.00

   Labourer                  75      232 762   3.22    1.34 (0.98 to 1.84)            0.94 (0.67 to 1.33)

   Other                     77      183 730   4.19    1.75 (1.28 to 2.39)\*\*\*      1.19 (0.82 to 1.71)

  Monthly income¶                                                                     

   \<15 000                  113     328 597   3.44    2.00 (1.20 to 3.33)\*\*        1.92 (1.10 to 3.33)\*

   15 000--19 999            101     318 118   3.17    1.84 (1.10 to 3.08)\*          1.97 (1.15 to 3.36)\*

   ≥20 000                   17      98 704    1.72    1.00                           1.00

  Urbanisation level††                                                                

   City                      97      399 858   2.43    1.00                           1.00

   Rural area                134     345 561   3.88    1.60 (1.23 to 2.08)\*\*\*      1.46 (1.12 to 1.90)\*\*

  Comorbidity                                                                         

   Diabetes                                                                           

    No                       197     718 779   2.74    1.00                           1.00

    Yes                      34      26 641    12.8    4.67 (3.24 to 6.73)\*\*\*      2.62 (1.77 to 3.87)\*\*\*

   Asthma                                                                             

    No                       202     719 903   2.81    1.00                           1.00

    Yes                      29      25 516    11.4    4.06 (2.75 to 5.99)\*\*\*      1.98 (1.27 to 3.07)\*\*

   COPD                                                                               

    No                       182     707 738   2.57    1.00                           1.00

    Yes                      49      37 681    13.0    5.07 (3.69 to 6.95)\*\*\*      2.01 (1.38 to 2.95)\*\*\*

   CLD                                                                                

    No                       186     655 200   2.84    1.00                           1.00

    Yes                      45      90 219    4.99    1.76 (1.27 to 2.43)\*\*\*      1.00 (0.71 to 1.42)

   Cancer                                                                             

    No                       228     741 180   3.08    1.00                           

    Yes                      3       4239      7.08    2.30 (0.74 to 7.19)            

   SLE/RA/immune disorders                                                            

    No                       231     745 075   3.10    1.00                           

    Yes                      0       345       0.00    --                             

   Organ transplant                                                                   

    No                       231     745 312   3.10    1.00                           

    Yes                      0       107       0.00    --                             

   Malnutrition                                                                       

    No                       223     741 266   3.01    1.00                           1.00

    Yes                      8       4154      19.3    6.38 (3.15 to 12.9)\*\*\*      3.60 (1.76 to 7.36)\*\*\*

   Obesity                                                                            

    No                       229     737 942   3.10    1.00                           

    Yes                      2       7478      2.67    0.86 (0.21 to 3.46)            

   Alcohol abuse                                                                      

    No                       209     714 370   2.93    1.00                           1.00

    Yes                      22      31 049    7.09    2.42 (1.56 to 3.77)\*\*\*      1.74 (1.10 to 2.74)\*

   Drug abuse                                                                         

    No                       220     724 902   3.03    1.00                           

    Yes                      11      20 517    5.36    1.77 (0.96 to 3.24)            

   Tobacco use disorder                                                               

    No                       227     739 856   3.07    1.00                           

    Yes                      4       5564      7.19    2.37 (0.88 to 6.39)            
  ---------------------------------------------------------------------------------------------------------------

\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

†Incidence rate per 10 000 PY.

‡Multivariable analysis controlling for age, sex, occupation, income, urbanisation and comorbidities of diabetes, asthma, COPD, CLD, malnutrition and alcohol abuse.

§Other occupations include primarily retired, unemployed and low-income populations.

¶1 new Taiwan dollar is equal to 0.03 US dollar.

††The urbanisation level is categorised by the population density of the residential area into two levels: city and rural area.

CLD, chronic liver disease and cirrhosis; COPD, chronic obstructive pulmonary disease; IRR, incidence rate ratio; PY, person-years; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

[Table 3](#T3){ref-type="table"} shows the incident empyema developed in the two cohorts by demographic status and comorbidity status. The incidence rates in each stratum were greater in the schizophrenia subgroups than in the comparison subgroups. The schizophrenia group to the comparison group IRRs and aHRs were significant for all strata. Significant IRRs ranged from 1.51 to 3.63 and significant aHRs ranged from 2.45 to 3.70. Comorbidity increased the incidence of pleural empyema in both cohorts for 3.74 and 3.51 per 10 000 person-years, respectively. The schizophrenia group to comparison group aHR showed a relatively greater impact for study individuals without comorbidities than those with comorbidity.

###### 

Incidence of pleural empyema and schizophrenia cohort to comparison cohort IRR and aHR

                         Schizophrenia   IRR (95% CI)   aHR‡ (95% CI)                                                      
  ---------------------- --------------- -------------- --------------- ----- --------- ------ --------------------------- ---------------------------
  Age (years)                                                                                                              
   20--49                30              297 238        1.01            96    307 059   3.13   3.10 (2.06 to 4.67)\*\*\*   2.77 (1.84 to 4.18)\*\*\*
   50--64                17              45 162         3.76            48    52 831    9.09   2.41 (1.39 to 4.19)\*\*     2.55 (1.45 to 4.49)\*\*
   ≥65                   20              29 584         6.76            20    13 546    14.8   2.15 (1.16 to 3.99)\*       2.68 (1.43 to 5.05)\*\*
  Sex                                                                                                                      
   Women                 12              182 640        0.66            40    177 729   2.25   3.43 (1.80 to 6.53)\*\*\*   3.70 (1.93 to 7.11)\*\*\*
   Men                   55              189 345        2.90            124   195 706   6.34   2.18 (1.59 to 2.99)\*\*\*   2.63 (1.90 to 3.65)\*\*\*
  Occupation§                                                                                                              
   Office worker         20              164 783        1.21            59    164 144   3.59   2.99 (1.80 to 4.96)\*\*\*   3.05 (1.83 to 5.11)\*\*\*
   Labourer              28              115 910        2.42            47    116 852   4.02   1.67 (1.04 to 2.66)\*       2.50 (1.53 to 4.08)\*\*\*
   Other                 19              91 291         2.08            58    92 439    6.27   3.01 (1.79 to 5.05)\*\*\*   3.41 (1.97 to 5.93)\*\*\*
  Monthly income¶                                                                                                          
   \<15 000              28              162 081        1.73            85    166 516   5.10   2.95 (1.93 to 4.53)\*\*\*   3.20 (2.07 to 4.94)\*\*\*
   15 000--19 999        35              158 330        2.21            66    159 788   4.13   1.87 (1.24 to 2.82)\*\*     2.49 (1.62 to 3.82)\*\*\*
   ≥20 000               4               51 573         0.78            13    47 131    2.76   3.63 (1.18 to 11.1)\*       3.64 (1.17 to 11.4)\*
  Urbanisation level††                                                                                                     
   City                  24              199 255        1.20            73    200 604   3.64   3.03 (1.91 to 4.80)\*\*\*   3.67 (2.29 to 5.90)\*\*\*
   Rural area            43              172 729        2.49            91    172 832   5.27   2.11 (1.47 to 3.04)\*\*\*   2.45 (1.69 to 3.56)\*\*\*
  Comorbidity‡‡                                                                                                            
   No                    26              283 934        0.92            96    276 098   3.48   3.81 (2.47 to 5.87)\*\*\*   3.73 (2.42 to 5.76)\*\*\*
   Yes                   41              88 050         4.66            68    97 338    6.99   1.51 (1.02 to 2.22)\*       2.27 (1.50 to 3.42)\*\*\*

*\**p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

†Incidence rate per 10 000 PY.

‡Multivariable analysis controlling for age, sex, occupation, income, urbanisation and comorbidities of diabetes, asthma, chronic obstructive pulmonary disease, chronic liver disease and cirrhosis, malnutrition and alcohol abuse.

§Other occupations include primarily retired, unemployed and low-income populations.

¶1 new Taiwan dollar is equal to 0.03 US dollar.

††The urbanisation level is categorised by the population density of the residential area into two levels: city and rural area.

‡‡Individuals with any comorbidity of diabetes, asthma, chronic obstructive pulmonary disease, chronic liver disease and cirrhosis, cancer, systemic lupus erythematosus/rheumatoid arthritis/immune disorders, organ transplant, malnutrition, obesity, alcohol abuse, drug abuse and tobacco use disorder were classified into the comorbidity group.

IRR, incidence rate ratio; PY, person-years.

[Table 4](#T4){ref-type="table"} shows a lower 30-day mortality rate from pleural empyema for the schizophrenic cohort than for the comparison cohort (6.71% vs 8.96%), with an adjusted OR of 0.95 (95% CI 0.30 to 3.01).

###### 

30-day mortality from pleural empyema in cohorts with and without schizophrenia and OR of mortality

                           Schizophrenia   
  ------------------------ --------------- ---------------------
  Deaths/events            6/67            11/164
  Mortality per 100        8.96            6.71
  Crude OR (95% CI)        1 (reference)   0.73 (0.26 to 2.06)
  Adjusted OR\* (95% CI)   1 (reference)   0.95 (0.30 to 3.01)

\*Multivariable analysis controlling for age, sex, occupation, income, urbanisation and comorbidities of diabetes, asthma, chronic obstructive pulmonary disease, chronic liver disease and cirrhosis, malnutrition and alcohol abuse.

Discussion {#s4}
==========

To the best of our knowledge, this is the first propensity-matched cohort study using population data to evaluate the risk of developing pleural empyema in patients with schizophrenia. The risk of pleural empyema is more than twofold greater than those without schizophrenia. Stratified analyses by age, sex, occupation, income, urbanisation and presence of comorbidities also showed that the incidence rates of pleural empyema were consistently higher in the schizophrenia cohort than in comparisons, and the aHRs for pleural empyema associated with schizophrenia were significant for all subgroups. In addition, the incidences of pleural empyema were higher in older people than in young people, higher in men than in women and in individuals with comorbidities than in those without comorbidities. These findings are in accordance with the general concepts.

The mechanism associating schizophrenia with the risk of developing pleural empyema remains largely unknown. Smoking is a well-known behaviour prevalent in patients with schizophrenia and has association with the development of pleural empyema. In addition, an unhealthy lifestyle, lack of self-care, poorer physical circumstances and health-risk activities may contribute to this condition.[@R15] Frequent medical visits and a prolonged hospital stay may also be contributing factors.[@R18] Moreover, patients with schizophrenia may reside in a long-term care facility. Pneumonia in these residents has been defined as a specific type, healthcare-associated pneumonia (HCAP).[@R24] The pathogens of HCAP are often multidrug-resistant bacteria, which is a potential risk factor for developing pleural empyema. Furthermore, patients with schizophrenia are at a higher risk of developing swallowing disorders, leading to aspiration pneumonia.[@R25] Pleural empyema is easily caused by the aspiration of mixed bacterial flora and other materials from the oropharyngeal cavity and even from the upper gastrointestinal tract. In addition, previous studies have suggested that the use of second-generation antipsychotics, such as clozapine, may increase the risk of pneumonia in patients with schizophrenia.[@R26] Clozapine has been associated with agranulocytosis, sialorrhea and impaired swallowing function; patients with this medication may thus have a greater risk for pneumonia.[@R29]

Patients with schizophrenia are at a markedly increased risk of premature death, particularly from thoracic infection and pneumonia. A large-scale study in the USA showed that the overall mortality rate was 3.7 times higher in patients with schizophrenia than in the general population.[@R30] The increased mortality was mainly from respiratory diseases: 9.9 times higher from COPD and 7.0 times higher from influenza and pneumonia. A study in Taiwan showed that patients with schizophrenia experienced a 3.09-fold increased risk of developing pneumonia, with an aHR of 1.39 for deaths from pneumonia.[@R16] In a Romanian study, autopsy findings in sudden unexpected deaths in inpatients with schizophrenia revealed that the top three specific causes were myocardial infarction (52.9%), pneumonia (11.8%) and airway obstruction (7.8%).[@R31] However, the present study showed no significant disparity in the 30-day mortality between the schizophrenic and comparison cohorts.

The strength of this study was using a large nationwide data to perform the propensity-matched evaluation assessing the pleural empyema risk for patients with schizophrenia. Confounding bias has been thus reduced in this inexpensive retrospective cohort study. The National Health Insurance programme has covered \>99.0% of the Taiwanese population. The universal health coverage reduces barriers to healthcare access for all citizens, regardless of their socioeconomic background and/or residential location.[@R32] The present study reflected a 'real-world' scenario by using the claims data, as schizophrenia, pleural empyema and comorbidities were diagnosed at clinics during medical consultations.

There are several limitations that should be considered when interpreting the study findings. First, we used the ICD-9-CM algorithm to define schizophrenia, pleural empyema and comorbidities. The diagnosis of schizophrenia is mostly accurate because it is a disease with catastrophic certificate. All other diagnoses depended on the competence of clinical physicians. An ad hoc committee established by the insurance authority was in charge of evaluating the claims data to prevent errors and violations. In addition, only the disease with at least two diagnosis codes identified within a year was included to increase the validity and accuracy. Second, the information on smoking, drinking, nutrition and other psychosocial and environmental factors were unavailable, which may affect the risk of pulmonary infections and consequent complications. Instead, we used the tobacco use disorder and alcohol abuse to substitute smoking and drinking, respectively, in the multivariable analysis for adjustment. Similarly, malnutrition is a crucial factor for pleural empyema development; however, it is unlikely to be identified adequately by relying on recorded diagnoses. In addition, institutional residence is a possible source of multiple-resistant infection, but the relevant data were unavailable. Furthermore, other clinical variables such as serum laboratory data, image reports and culture results were not available to our study.[@R33]

Conclusion {#s5}
==========

This study provides evidence that patients with schizophrenia are at an elevated risk of developing pleural empyema. The risk increases further for those with comorbidity. Patients with schizophrenia suffering from pneumonia or other thoracic infection need close surveillance for potential risk of development of pleural empyema and disease-related mortality.
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